Allergan, the target of takeover speculation, is shopping for acquisitions of its own, CEO David Pyott told Bloomberg in an interview.

Pyott declined to say whether another drugmaker offered to buy Allergan, a maker of wrinkle-remedy products such as Botox. Shares of the Irvine, Calif., company rose more than 13% Tuesday following a report that said GlaxoSmithKline ( GSK) might be interested in acquiring the company.

The Allergan CEO didn't rule out a sale, Bloomberg reports. "Somebody would have to come out with a very compelling proposition," Pyott told Bloomberg.

Allergan is seeking purchases that would augment its focus on cosmetics, specialty eye care, obesity treatment, urology or neurology, Pyott said.

"We are constantly looking at new opportunities," Pyott said, Bloomberg reports. "We have well over a billion in the bank, and we could do a multibillion-dollar deal if it made sense."

Company spokespeople from Allergan and Glaxo declined to comment on the report from Web site dealreporter.com.

If you liked this article you might like

Jim Cramer: Drug Stocks on the Move

Jim Cramer: Drug Stocks on the Move

Allergan Exec on Medical Aesthetics: 'The Future Is About Market Expansion'

Allergan Exec on Medical Aesthetics: 'The Future Is About Market Expansion'

Cramer: 10 Stock Surprises

Cramer: 10 Stock Surprises

Purdue Pharma to Downplay Opioids, Dump 50% of Sales Staff

Purdue Pharma to Downplay Opioids, Dump 50% of Sales Staff

Generic Drug Makers Hurt By Latest Federal Government Budget

Generic Drug Makers Hurt By Latest Federal Government Budget